MetaCap

Nektar Therapeutics (NKTR) vs Seaport Therapeutics (SPTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nektar Therapeutics is the larger company by market cap ($1.03 billion vs $966.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NKTR-65.07%SPTX-9.02%
+46%-12%-70%
May 1, 20261 yearNov 20, 2026
NKTR-65.07%SPTX-9.02%
+30%-20%-70%
Apr 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NKTR versus SPTX key metrics
MetricNKTRSPTX
Share price$30.20$18.05
Market cap$1.03B$966.23M
1-day change-7.19%-1.47%
YTD return-28.57%—
1-year return-44.36%—
5-year return-82.04%—
EPS (TTM)$-22.47$-4.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$55.23M—
Revenue growth (YoY)-43.89%—
Net income (latest FY)$-164.08M—
Gross margin100.00%—
Operating margin-253.66%—
Net margin-297.07%—
52-week high$109.00$28.38
52-week low$30.13$14.85
Distance from 52-week high-72.29%-36.40%
Analyst consensusbuystrong_buy
Avg. price target upside+336.82%+105.71%
Average volume1.12M259.83K
Shares outstanding34.21M53.53M
Employees6359
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Nektar Therapeutics

NKTR stock →

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees

About Seaport Therapeutics

SPTX stock →

Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety.

Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees

NKTR vs SPTX FAQ

Which is bigger, Nektar Therapeutics or Seaport Therapeutics?

Nektar Therapeutics (NKTR) is larger, with a market capitalization of $1.03B compared with $966.23M for Seaport Therapeutics (SPTX).

Are Nektar Therapeutics and Seaport Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons